163 related articles for article (PubMed ID: 34807513)
1. Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
Sullivan SD; Freemantle N; Gupta RA; Wu J; Nicholls CJ; Westerbacka J; Bailey TS
Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00306. PubMed ID: 34807513
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sullivan SD; Bailey TS; Roussel R; Zhou FL; Bosnyak Z; Preblick R; Westerbacka J; Gupta RA; Blonde L
Diabetes Obes Metab; 2018 Sep; 20(9):2148-2158. PubMed ID: 29938887
[TBL] [Abstract][Full Text] [Related]
3. Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3).
Bailey TS; Wu J; Zhou FL; Gupta RA; Menon AA; Berhanu P; Westerbacka J; Van Vleet J; Blonde L
Diabetes Obes Metab; 2019 Nov; 21(11):2384-2393. PubMed ID: 31264346
[TBL] [Abstract][Full Text] [Related]
4. Real-world persistence, adherence, health care resource utilization, and costs in people with type 2 diabetes switching from a first-generation basal insulin to a second-generation (insulin glargine 300 U/mL) vs an alternative first-generation basal insulin.
Wright EE; Malone DC; Trujillo JM; Gill J; Huse S; Li X; Zhou FL; Preblick R; Reid T
J Manag Care Spec Pharm; 2022 Jun; 28(6):592-603. PubMed ID: 35352995
[No Abstract] [Full Text] [Related]
5. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
[TBL] [Abstract][Full Text] [Related]
6. Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme.
Blonde L; Bailey T; Sullivan SD; Freemantle N
Diabetes Obes Metab; 2021 Aug; 23(8):1713-1721. PubMed ID: 33881797
[TBL] [Abstract][Full Text] [Related]
7. Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
Zhou FL; Ye F; Berhanu P; Gupta VE; Gupta RA; Sung J; Westerbacka J; Bailey TS; Blonde L
Diabetes Obes Metab; 2018 May; 20(5):1293-1297. PubMed ID: 29272064
[TBL] [Abstract][Full Text] [Related]
8. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
Sullivan SD; Nicholls CJ; Gupta RA; Menon AA; Wu J; Westerbacka J; Bosnyak Z; Frias JP; Bailey TS
Diabetes Obes Metab; 2019 Sep; 21(9):2123-2132. PubMed ID: 31144445
[TBL] [Abstract][Full Text] [Related]
9. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
[TBL] [Abstract][Full Text] [Related]
10. Therapeutically interchangeable? A study of real-world outcomes associated with switching basal insulin analogues among US patients with type 2 diabetes mellitus using electronic medical records data.
Levin P; Wei W; Miao R; Ye F; Xie L; Baser O; Gill J
Diabetes Obes Metab; 2015 Mar; 17(3):245-53. PubMed ID: 25359227
[TBL] [Abstract][Full Text] [Related]
11. Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G study.
Bailey TS; Gill J; Jones S M; Shenoy L; Nicholls C; Westerbacka J
Diabetes Obes Metab; 2022 Aug; 24(8):1617-1622. PubMed ID: 35491520
[TBL] [Abstract][Full Text] [Related]
12. Real-World Health Outcomes of Insulin Glargine 300 U/mL vs Insulin Glargine 100 U/mL in Adults With Type 1 and Type 2 Diabetes in the Canadian LMC Diabetes Patient Registry: The REALITY Study.
Abitbol A; Brown RE; Jiandani D; Sauriol L; Aronson R
Can J Diabetes; 2019 Oct; 43(7):504-509.e1. PubMed ID: 31256905
[TBL] [Abstract][Full Text] [Related]
13. Much ado about nothing? A real-world study of patients with type 2 diabetes switching Basal insulin analogs.
Wei W; Zhou S; Miao R; Pan C; Xie L; Baser O; Gill J
Adv Ther; 2014 May; 31(5):539-60. PubMed ID: 24831915
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the clinical effectiveness and safety of insulin glargine 300 U/mL in individuals with type 2 diabetes uncontrolled on basal insulin: A real-world evidence study from Saudi Arabia (EVOLUTION).
Al Malki F; El Damanhoury B; Othman A; Alghamdi Z; AlQahtani M; Madgy A; Chouikrat Z
Diabetes Obes Metab; 2023 Oct; 25(10):2869-2877. PubMed ID: 37485767
[TBL] [Abstract][Full Text] [Related]
15. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
16. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
[TBL] [Abstract][Full Text] [Related]
17. Rates of Hypoglycemia Predicted in Patients with Type 2 Diabetes on Insulin Glargine 300 U/ml Versus First- and Second-Generation Basal Insulin Analogs: The Real-World LIGHTNING Study.
Pettus J; Roussel R; Liz Zhou F; Bosnyak Z; Westerbacka J; Berria R; Jimenez J; Eliasson B; Hramiak I; Bailey T; Meneghini L
Diabetes Ther; 2019 Apr; 10(2):617-633. PubMed ID: 30767173
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).
Terauchi Y; Koyama M; Cheng X; Sumi M; Riddle MC; Bolli GB; Hirose T;
Diabetes Metab; 2017 Oct; 43(5):446-452. PubMed ID: 28433560
[TBL] [Abstract][Full Text] [Related]
19. Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
Meneghini L; Blonde L; Gill J; Dauchy A; Bacevicius A; Strong J; Bailey TS
Diabetes Obes Metab; 2020 Nov; 22(11):1995-2003. PubMed ID: 32538550
[TBL] [Abstract][Full Text] [Related]
20. Lower risk of hypoglycaemia and greater odds for weight loss with initiation of insulin detemir compared with insulin glargine in Turkish patients with type 2 diabetes mellitus: local results of a multinational observational study.
Damci T; Emral R; Svendsen AL; Balkir T; Vora J;
BMC Endocr Disord; 2014 Jul; 14():61. PubMed ID: 25048824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
